Alfuzosin for symptomatic benign prostatic hyperplasia: Long-term experience

Journal of Urology

Volumn 175, Issue 1, 2006, Pages 35-42

  McVary, Kevin T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adrenergic alpha antagonists; Alfuzosin; Prostate; Prostatic hyperplasia; Urinary incontinence

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; VASODILATOR AGENT;

ASTHENIA; CLINICAL TRIAL; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; MALAISE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; RISK FACTOR; TIME SERIES ANALYSIS; URETHRA; URINARY TRACT DISEASE; URINE RETENTION; URINE VOLUME; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; HUMANS; MALE; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUINAZOLINES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TIME FACTORS;

EID: 29144498285     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00032-7     Document Type: Review

References (51)

1. S.J. Berry, D.S. Coffey, P.C. Walsh, L.L. Ewing The development of human benign prostatic hyperplasia with age J Urol 132 1984 474
2. W.M. Garraway, G.N. Collins, R.J. Lee High prevalence of benign prostatic hypertrophy in the community Lancet 338 1991 469
3. AUA Practice Guidelines Committee AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations J Urol 170 2003 530
4. C.G. Roehrborn, J.D. McConnell Etiology, pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia P.C. Walsh A.B. Retik E.D. Vaughan Jr. A.J. Wein 8th ed. Campbell's Urology vol. 2 2002 W. B. Saunders Co Philadelphia 1297 1336 sect. VI, chapt. 38
5. R.S. Kirby The natural history of benign prostatic hyperplasia what have we learned in the last decade? Urology 56 suppl 2000 3
6. A. Thorpe, D. Neal Benign prostatic hyperplasia Lancet 361 2003 1359
7. C.C. Schulman Long-term aspects of medical treatment of BPH Eur Urol 40 suppl 2001 8
8. C.G. Roehrborn, R. Bruskewitz, G.C. Nickel, S. Glickman, C. Cox, R. Anderson The PLESS Study Group Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes Eur Urol 37 2000 528
9. A. Jardin, K.-E. Andersson, C. Chapple α1-Adrenoceptor antagonists in the treatment of BPH C. Chatelain G.E. Denis K.T. Foo K. Khoury J. McConnell Benign Prostatic Hyperplasia 2001 Health Publication, Ltd Plymouth, United Kingdom 461 477
10. M. Caine, A. Pfau, S. Perlberg The use of alpha-adrenergic blockers in benign prostatic obstruction Br J Urol 48 1976 255
11. B. Djavan, M. Marberger A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction Eur Urol 36 1999 1
12. K.E. Andersson Mode of action of alpha-1-adrenoreceptor antagonists in the treatment of lower urinary tract symptoms BJU Int 85 suppl 2000 12
13. R.S. Kirby Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia Eur Urol 33 suppl 1998 19
14. N. Mottet, F. Bressolle, V. Delmas, M. Robert, P. Costa Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration Eur Urol 44 2003 101
15. A.J. Noble, R. Chess-Williams, C. Couldwell, K. Furukawa, T. Uchyiuma, C. Korstanje The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes Br J Pharmacol 120 1997 231
16. Y. Suzuki, A. Kanada, Y. Okaya, K. Aisaka Effect of JTH-601, a novel alpha(1)-adrenoceptor antagonist, on prostate function in dogs Eur J Pharmacol 394 2000 123
17. B. Lukacs, J.C. Grange, D. Comet, C. McCarthy Prospective follow-up of 3,228 patients suffering from clinical benign prostatic hyperplasia (BPH) treated for 3 years with alfuzosin in general practice Prog Urol 9 1999 271
18. R. Vela Navarrete, R. Gabriel, R. Barajas, I. Ausin Prostatic benign hypertrophy review of effectiveness, tolerance, and impact on quality of life of prolonged treatment with alfuzosin Actas Urol Esp 24 2000 120
19. C.G. Roehrborn, P. van Kerrebroeck, J. Nordling Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia a pooled analysis of three double-blind, placebo-controlled studies BJU Int 92 2003 257
20. T. Nieminen, R. Ylitalo, T. Koobi, P. Ylitalo, M. Kahonen The vasodilatory effect of alfuzosin and tamsulosin in passive orthostasis a randomised, double-blind, placebo-controlled study Eur Urol 47 2005 340
21. Flomax® (tamsulosin hydrochloride) capsules prescribing information Physicians' Desk Reference® 58th ed. 2004 Thomson PDR Montvale 1006 1009
22. Uroxatral® prescribing information. Available at http://www.sanofi- synthelabous.com/products/pi_uroxatral/pi_uroxatral.html. Accessed October 31, 2003
23. P. van Kerrebroeck, A. Jardin, K.U. Laval, P. van Cangh ALFORTI Study Group Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia Eur Urol 37 2000 306
24. P. van Kerrebroeck, A. Jardin, P. van Cangh, K.U. Laval ALFORTI Study Group Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia open-label extension study Eur Urol 41 2002 54
25. Roehrborn, C. G., van Kerrebroeck, P. and Nordling, J.: Safety and efficacy of alfuzosin 10 mg once daily in the treatment of lower urinary tract symptoms (LUTS) and clinical benign prostatic hyperplasia (BPH): a pooled analysis of three double-blind, placebo-controlled studies. Unpublished data
26. A. Jardin, H. Bensadoun, M.C. Delauche-Cavallier, A. Stalla-Bourdillon, P. Attali BPHALF Group Long-term treatment of benign prostatic hyperplasia with alfuzosin a 24-30 month survey Br J Urol 74 1994 579
27. B. Lukacs, J.C. Grange, C. McCarthy, D. Comet BPM Group in General Practice Clinical uroselectivity a 3-year follow-up in general practice Eur Urol 33 suppl 1998 28
28. B. Lukacs, A. Leplege, P. Thibault, A. Jardin Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners 1-year results Urology 48 1996 731
29. B. Lukacs, J.C. Grange, D. Comet BPM Group in General Practice One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire Urology 55 2000 540
30. The Italian Alfuzosin Co-Operative Group Safety, efficacy and impact on patients' quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH Eur Urol 37 2000 680
31. S. Boyarsky, G. Jones, D.F. Paulson, G.R. Prout Jr. A new look at bladder neck obstruction by the food and drug administration regulators guide lines for investigation of benign prostatic hypertrophy Trans Am Assoc Genitourin Surg 68 1976 29
32. B. Lukacs, J.C. Grange, D. Comet, C. McCarthy Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in general practice Prostate Cancer Prostatic Dis 1 1998 276
33. M.J. Barry, F.J. Fowler Jr., M.P. O'Leary, R.C. Bruskewitz, H.L. Holtgrewe, W.K. Mebust Measurement Committee of the American Urological Association Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes J Urol 148 1992 1558
34. A. Jardin, H. Bensadoun, M.C. Delauche-Cavallier, P. Attali BPHALF Group Long-term treatment of benign prostatic hyperplasia with alfuzosin a 12-18 month assessment Br J Urol 72 1993 615
35. C.G. Roehrborn Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia a randomized, placebo-controlled trial Urology 58 2001 953
36. M. Braun, G. Wassmer, T. Klotz, B. Reifenrath, M. Mathers, U. Engelmann Epidemiology of erectile dysfunction results of the 'Cologne Male Survey' Int J Impot Res 12 2000 305
37. R. Rosen, J. Altwein, P. Boyle, R.S. Kirby, B. Lukacs, E. Meuleman Lower urinary tract symptoms and male sexual dysfunction the multinational survey of the aging male (MSAM-7) Eur Urol 44 2003 637
38. B. Lukacs, C. McCarthy, J.C. Grange QOL BPH Study Group in General Practice Long-term quality of life in patients with benign prostatic hypertrophy preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin Eur Urol 24 suppl 1993 34
39. T.J. Peters The relationship between LUTS and sexual function Prostate Cancer Prostatic Dis 4 2001 S2
40. R. Rosen, M. O'Leary, J. Altwein, P. Boyle, F. Giuliano, R. Kirby Ejaculatory disorders are frequent and bothersome in ageing males with LUTS a worldwide survey (MSAM-7) Eur Urol 2 suppl 2003 94
41. K.T. McVary Sexual dysfunction in men with lower urinary tract symptoms and benign prostatic hyperplasia an emerging link BJU Int 91 2003 770
42. K.T. McVary, K.E. McKenna The relationship between erectile dysfunction and lower urinary tract symptoms epidemiological, clinical, and basic science evidence Curr Urol Rep 5 2004 251
43. R.J. van Moorselaar, R. Hartung, M. Emberton, N. Harving, H. Matzkin Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction BJU Int 95 2005 603
44. K. McKeage, G.L. Plosker Alfuzosin a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia Drugs 62 2002 633
45. R.C. Flanigan, D.J. Reda, J.H. Wasson, R.J. Anderson, M. Abdellatif, R.C. Bruskewitz 5-Year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia a Department of Veterans Affairs cooperative study J Urol 160 1998 12
46. J.D. McConnell, C.G. Roehrborn, O.M. Bautista, G.L. Andriole Jr., C.M. Dixon, J.W. Kusek The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387
47. A. Jardin, H. Bensadoun, M.C. Delauche-Cavallier, P. Attali The BPH-ALF Group Alfuzosin for treatment of benign prostatic hypertrophy Lancet 337 1991 1457
48. J.D. McConnell, R. Bruskewitz, P. Walsh, G. Andriole, M. Lieber, H.L. Holtgrewe Finasteride Long-Term Efficacy and Safety Study Group The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia N Engl J Med 338 1998 557
49. J.H. Wasson, D.J. Reda, R.C. Bruskewitz, J. Elinson, A.M. Keller, W.G. Henderson The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia N Engl J Med 332 1995 75
50. S.A. McNeill, P.D. Daruwala, I.D. Mitchell, M.G. Shearer, T.B. Hargreave Sustained-release alfuzosin and trial without catheter after acute urinary retention a prospective, placebo-controlled trial BJU Int 84 1999 622
51. Data on file 2005 Sanofi-Synthelabo, Inc Bridgewater, New Jersey